Control of the iRhom2 protein may hold the key to preventing Alzheimer's disease

June 19, 2018, CORDIS
Control of the iRhom2 protein may hold the key to preventing Alzheimer’s disease
Credit: IRHOM2 in AD

It is known that the onset of Alzheimer's disease (AD) is associated with the accumulation of Amyloid beta (Aβ) peptides in small molecular clusters known as oligomers. These trigger the formation of so-called 'neurofibrillary tangles' within neurons hamper their workings, ultimately causing cell death and so significant cognitive decline. Very large Aβ oligomers which form plaques outside neurons, alongside neuroinflammation have also been found to play a key part in the progression of the disease.

The EU-funded iRhom2 in AD project took as its starting point the protein iRhom2, which has been identified as a for AD due to its pro-inflammatory properties. The team were able to explore further the influence of iRhom2 on neuroinflammation in mice.

Modulating iRhom2

iRhom2 recently emerged as a protein of note in AD as it aids the maturation of an enzyme called TACE (tumor necrosis factor-α converting enzyme) guiding it towards a cell's plasma membrane where the enzyme releases a cell-signalling cytokine (TNFα), implicated in the regulation of inflammatory processes. While mice studies have shown that TNFα-dependent inflammation can lead to sepsis and rheumatoid arthritis, it is also thought that the process contributes to neuroinflammatory signalling events, which can cause harm in the brain.

The EU-funded iRhom2 in AD project worked with mice that are prone to develop the hallmarks of AD, amyloid plaques and memory deficits. The team genetically altered iRhom2 in the mice then analysed the progression of the pathology using an array of biochemical and histological methods, together with a number of behavioural tests to assess cognitive decline.

The results were somewhat surprising as project coordinator Prof. Dr. Stefan Lichtenthaler recalls, "We initially hypothesised that iRhom2 would affect one specific aspect of neuroinflammation in AD. What we discovered was even more exciting as it actually affects several different aspects of neuroinflammation simultaneously. So modulating iRhom2 appears particularly well suited to interfere with AD."

Beyond treatment to prevention

While AD is mainly a disease of the elderly, 5-10 % of all cases may have an earlier onset, especially when it comes to cases of familial AD. As Prof. Lichtenthaler elaborates, "As the first changes in an AD brain happen 25 years before the onset of AD symptoms, in order to stop the disease, we have to treat the causes and not just the symptoms, obviously years before disease onset. We need to move beyond treatment to prevention."

Yet, until very recently, all potential cures have been tested in patients that had already developed the disease and so by definition, are applied too late in the process. Drugs are only now being tested before the onset of symptoms. But these longitudinal studies, which follow subjects from being disease-free until they develop symptoms, will not yield results until at least 2024. Another hurdle to overcome is the need for a new diagnostic that can indicate who is likely to develop the disease in the coming years.

Identifying iRhom2 as a new therapeutic target for AD sets the stage for the future development of drugs which can modulate the protein. As Prof. Lichtenthaler says, "Such drugs used for the treatment of the disease could have a terrific impact on improving the lives of many people. Crucially, this therapy could be used not only to prevent the disease, but also potentially to help patients that do already have symptoms."

Currently the project team are working to better understand the precise mechanism by which iRhom2 influences AD at the molecular level and apply this knowledge for drugs that can block the activity of iRhom2 in patients.

Explore further: New insights into the release of molecules involved in inflammatory diseases

Related Stories

New insights into the release of molecules involved in inflammatory diseases

November 2, 2017
In a recent study published in Cell Reports, a research team led by Colin Adrain, from the Instituto Gulbenkian de Ciência (IGC, Portugal), discovered the mechanism that controls the release of important molecules that trigger ...

Why thick skin develops on palms and soles, and its links to cancer

February 1, 2017
Scientists from Queen Mary University of London have discovered that foot callouses/keratoderma (thickened skin) can be linked to cancer of the oesophagus (gullet), a disease which affects more than 8000 people in the UK ...

Researchers identify new target for rheumatoid arthritis

January 25, 2013
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially ...

Can nanotechnology help treat Alzheimer's?

June 19, 2018
Alzheimer's disease (AD) is the most common form of dementia. It takes a devastating toll on patients and family members, who are usually the caregivers. Current drugs only treat symptoms of AD, not its causes.

Saving neurons may offer new approach for treating Alzheimer's disease

November 6, 2017
Treatment with a neuroprotective compound that saves brain cells from dying also prevents the development of depression-like behavior and the later onset of memory and learning problems in a rat model of Alzheimer's disease. ...

Researchers successfully reverse Alzheimer's disease in mouse model

February 14, 2018
A team of researchers from the Cleveland Clinic Lerner Research Institute have found that gradually depleting an enzyme called BACE1 completely reverses the formation of amyloid plaques in the brains of mice with Alzheimer's ...

Recommended for you

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

Detecting signs of neurodegeneration earlier and more accurately

November 30, 2018
Signs of neurodegenerative diseases, appearing years before the emergence of clinical manifestations, can be detected during the examination of medical samples by means of fluorescence microscopy by using new sensitive and ...

Never-before-seen DNA recombination in the brain linked to Alzheimer's disease

November 21, 2018
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer's disease brains. The study, published today ...

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.